ZIOPHARM Oncology, Inc. (WEK)

Overview

Alaunos Therapeutics, Inc. is a clinical-stage company focused on the development of innovative cell therapies for cancer treatment. With a keen emphasis on oncology, Alaunos is pioneering the advancement of adoptive TCR (T-cell receptor) engineered T-cell therapies aimed at addressing a range of malignancies. The company’s commitment to innovation is underscored by its collaboration with prominent institutions, including The University of Texas MD Anderson Cancer Center and the National Cancer Institute, alongside a strategic license agreement with PGEN Therapeutics, Inc. Initially founded in 2003 as ZIOPHARM Oncology, Inc., it underwent a rebranding to Alaunos Therapeutics, Inc. in January 2022, marking a new chapter in its mission to combat cancer. Based in Houston, Texas, Alaunos Therapeutics is propelling forward in its quest to leverage cutting-edge science for the benefit of patients worldwide.

Products and Services

• TCR Library

  This product is currently undergoing a Phase I/II clinical trial and represents a significant advancement in the field of TCR engineering. The library consists of 12 TCRs that are reactive to mutations in key cancer-related genes such as KRAS, TP53, and EGFR. The focus of this technology is on treating a spectrum of cancers, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The TCR Library exemplifies Alaunos’ commitment to targeting some of the most challenging mutations in oncology.

• hunTR

  The hunTR technology showcases Alaunos Therapeutics’ innovative approach to cancer therapy. Described as a human neoantigen T-cell receptor engine, hunTR is designed to identify and target neoantigens, which are unique markers found on cancer cells. This precision-targeted approach enables hunTR to potentially deliver more personalized and effective cancer treatments, underscoring the company’s dedication to pushing the boundaries of cancer therapy.